Shots:Ventus Therapeutics has entered a multi-year collaboration with Genentech to discover and optimize novel small-molecule drugs for major diseases using its ReSOLVE platformAs per the deal, Ventus will utilize its ReSOLVE platform to identify small-molecule leads for multiple targets, while Genentech will be responsible for preclinical, clinical, and commercial development. Ventus will receive…
Shots:BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolioAs per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 & RNA platform, in an all-cash transaction of $1.5BOTX-201 is a preclinical circular RNA therapy encoding a CD19 CAR for in vivo expression delivered via…
Shots:Evaxion has granted Merck the rights to EVX-B3, a preclinical vaccine candidate under their Sep 2024 option & license agreementAs per the deal, Merck will assume full responsibility & costs of further development of EVX-B3 in exchange for $7.5M upfront & ~$592M in development, regulatory & sales milestones, with net sales-based royaltiesEVX-B3…
Shots:Jazz Pharmaceuticals has entered into a global license agreement with Saniona to develop SAN2355 for epilepsy & other potential indicationsAs per the deal, Jazz will lead & fund development, regulatory filings, & global commercialization in exchange for $42.5M upfront, ~$192.5M in development & regulatory milestones (incl. $7.5M at P-I initiation), ~$800M in commercial milestones, &…
Shots:Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs
As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan…
Shots: Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…

